The EC approval is based on results from the Phase III EMPEROR-Preserved trial of 10mg empagliflozin versus placebo.
Lonza completed a laboratory expansion project at its API manufacturing facility in Nansha, China.
Results showed a clinically meaningful prevention of bleeds in people with severe haemophilia A
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.